News

Pretzel Therapeutics has received Fast Track Designation from the US Food and Drug Administration (FDA) for PX578, an investigational treatment for POLG-mediated primary mitochondrial disorders, also known as POLG disease.

PTC Therapeutics has completed its previously announced agreement with Sangamo Therapeutics to acquire ST-920 (isaralgagene civaparvovec), a one-time AAV gene therapy candidate being developed for Fabry disease.

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients

Eisai and Biogen have received approval in Japan for LEQEMBI Pen, a subcutaneous (SC) formulation of lecanemab, for the treatment of early Alzheimer’s disease (AD).

VaxThera S.A.S., a Colombian biotechnology company developing and manufacturing vaccines and biological products, has entered into an agreement with Codagenix Inc. to exclusively license

Evonik has started construction of a biotechnology expansion at its Fermas site in Slovenská Ľupča, Slovakia.

Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL-201, an investigational treatment for Duchenne muscular dystrophy (DMD).

University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers.

MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational inhaled GLP-1 therapy for weight management.

RiboX Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for RXRG001, an investigational treatment